分子诊断在胶质瘤分类中的研究进展  

Progress of Molecular Diagnosis in the Classification of Glioma

作　　者：万晓楠[1] 胡增春[2] 马辉[3] 韩爽 王冠宇[2] WAN Xiao-nan;HU Zeng-chun;MA Hui(Department of Neurosurgery,Dalian Central Hospital,Dalian 116023,China)

机构地区：[1]大连市中心医院神经外三科,辽宁大连116033 [2]大连医科大学附属第二医院神经外科,辽宁大连116021 [3]大连医科大学附属第二医院药剂科,辽宁大连116021 [4]大连医科大学附属第二医院检验科,辽宁大连116021

出　　处：《医学与哲学（B）》2018年第6期51-54,59,共5页Medicine & Philosophy(B)

摘　　要：胶质瘤的治疗及预后仍面临巨大挑战,最近随着对其生物学行为的深入研究,尤其是关键基因和分子的发现,WHO更新了胶质瘤的诊断和分类标准。这些更新一方面要求我们系统地回顾分析既往的病例资料,更重要的是,需要对未来的相关临床治疗和基础研究进行重新思考和设计。本文总结了最近文献中的胶质瘤分类的重要基因和分子,以便指导相应临床治疗方案的选择,同时这些基因和分子也是胶质瘤治疗的新靶点,期望能对未来的相关基础研究有所帮助。The treatment and prognosis of glioma still face great challenges.Recently,with the in-depth study of its biological behavior,especially the discovery of key genes and molecules,WHO has updated the diagnosis and classification criteria of glioma.These updates do not only require a systematic review of the analysis of previous case data,but also need rethinking and designing related clinical and basic research in the future.This article summarizes the important genes and molecules of glioma classification in recent literature,so as to guide the selection of the corresponding clinical treatment schemes,and these genes and molecules are also the new targets for the treatment of glioma.These research hope to be helpful to the relevant basic research in the future.

关 键 词：胶质瘤 分子诊断 基因检测 

分 类 号：R730.264[医药卫生—肿瘤]